Patient characteristics and previous therapies (N = 34)
| Characteristic . | N (%) . |
|---|---|
| Age, y | |
| Median | 67 |
| Range | 42-82 |
| Sex | |
| Female | 13 (38) |
| Male | 21 (62) |
| Performance status | |
| 0 | 20 (59) |
| 1 | 11 (32) |
| 2 | 3 (9) |
| Paraprotein type | |
| IgA | 7 (21) |
| IgG | 13 (38) |
| Free light chain only | 14 (41) |
| N of prior systemic therapy lines | |
| Median | 5 |
| Range | 2-10 |
| Prior ASCT | 26 (76) |
| Time from last dose of prior therapy to registration, d | |
| Median | 27 |
| Range | 3-402 |
| Known FISH poor-risk cytogenetics: del 17p, t(4;14), or t(14;16) | 13 (38) |
| Hemoglobin, g/L | |
| Median | 105 |
| Range | 77-145 |
| Platelets, × 109/L | |
| Median | 149 |
| Range | 17-337 |
| Prior BTZ | |
| N of lines | |
| Median | 2 |
| Range | 1-5 |
| N of cycles | |
| Median | 11 |
| Range | 3-33 |
| Refractory* | 34 (100) |
| BTZ + LEN | |
| Exposed | 34 (100) |
| Refractory | 27 (79) |
| BTZ + POM | |
| Exposed | 16 (47) |
| Refractory | 15 (44) |
| BTZ + CFZ | |
| Exposed | 2 (6) |
| Refractory | 2 (6) |
| BTZ + LEN + POM | |
| Exposed | 16 (47) |
| Refractory | 13 (38) |
| BTZ + LEN + POM + CFZ | |
| Exposed | 1 (3) |
| Refractory | 1 (3) |
| Characteristic . | N (%) . |
|---|---|
| Age, y | |
| Median | 67 |
| Range | 42-82 |
| Sex | |
| Female | 13 (38) |
| Male | 21 (62) |
| Performance status | |
| 0 | 20 (59) |
| 1 | 11 (32) |
| 2 | 3 (9) |
| Paraprotein type | |
| IgA | 7 (21) |
| IgG | 13 (38) |
| Free light chain only | 14 (41) |
| N of prior systemic therapy lines | |
| Median | 5 |
| Range | 2-10 |
| Prior ASCT | 26 (76) |
| Time from last dose of prior therapy to registration, d | |
| Median | 27 |
| Range | 3-402 |
| Known FISH poor-risk cytogenetics: del 17p, t(4;14), or t(14;16) | 13 (38) |
| Hemoglobin, g/L | |
| Median | 105 |
| Range | 77-145 |
| Platelets, × 109/L | |
| Median | 149 |
| Range | 17-337 |
| Prior BTZ | |
| N of lines | |
| Median | 2 |
| Range | 1-5 |
| N of cycles | |
| Median | 11 |
| Range | 3-33 |
| Refractory* | 34 (100) |
| BTZ + LEN | |
| Exposed | 34 (100) |
| Refractory | 27 (79) |
| BTZ + POM | |
| Exposed | 16 (47) |
| Refractory | 15 (44) |
| BTZ + CFZ | |
| Exposed | 2 (6) |
| Refractory | 2 (6) |
| BTZ + LEN + POM | |
| Exposed | 16 (47) |
| Refractory | 13 (38) |
| BTZ + LEN + POM + CFZ | |
| Exposed | 1 (3) |
| Refractory | 1 (3) |
ASCT, autologous stem-cell transplantation; BTZ, bortezomib; CFZ, carfilzomib; FISH, fluorescence in situ hybridization; Ig, immunoglobulin; LEN, lenalidomide; POM, pomalidomide.
Refractory disease was defined as either a ≤25% response, based on paraprotein levels, or progressive disease during therapy or within 60 days after completion of therapy. Bortezomib must have been administered at ≥1.0 mg/m2 with ≥2 applications in ≤28 days per cycle, when combined with an alkylating agent, anthracycline, or immunomodulatory drug, or with 4 applications in ≤28 days when administered as monotherapy or combined with a glucocorticosteroid.